CML/RAGE signal induces calcification cascade in diabetes by unknown
Wang et al. Diabetol Metab Syndr  (2016) 8:83 
DOI 10.1186/s13098-016-0196-7
RESEARCH
CML/RAGE signal induces calcification 
cascade in diabetes
Zhongqun Wang1, Lihua Li2, Rui Du3, Jinchuan Yan1*, Naifeng Liu4*, Wei Yuan1, Yicheng Jiang5, Suining Xu1, 
Fei Ye1, Guoyue Yuan6, Baohai Zhang1 and Peijing Liu1
Abstract 
Objective: Vascular calcification is a significant predictor of coronary heart disease events, stroke, and lower-limb 
amputation. Advanced glycation end-products (AGEs) play a key role in the development of vascular calcification. 
However, the role of Nε-carboxymethyl-lysine (CML), a major active ingredient of heterogeneous AGEs, in the devel-
opment of atherosclerotic calcification in diabetic patients and the underlying mechanism remain unclear. Hence, the 
role and the mechanism of CML in the transmission pathway of diabetic calcification cascade were investigated in the 
present study.
Methods: In vivo and in vitro investigations were performed. In study I, 45 diabetic patients hospitalized for above-
knee amputation in the Department of Orthopedics, Affiliated Hospital of Jiangsu University were recruited from 
February 2010 to June 2015. The patients were categorized based on the severity of anterior tibial artery stenosis, 
which was assessed by color Doppler ultrasound, into mild stenosis (0% < stenosis < 50%, n = 15), moderate stenosis 
(50 ≤ stenosis < 70%, n = 15), and severe stenosis/occlusion groups (70 ≤ stenosis ≤ 100%, n = 15). In study II, the 
specific mechanism of CML in the transmission pathway of the diabetic calcification cascade signal was investigated 
in A7r5 aortic smooth muscle cells under high-lipid, apoptosis-coexisting conditions. ELISA (for serum CML concentra-
tion of patients), ultrasound (for plaque size, calcification, blood flow filling, vascular stenosis etc.), H&E staining (for 
plaque morphology), vonKossa staining (for qualitative analysis of calcification), calcium content assay (for quantita-
tive analysis of calcification), and Western blot analyses of CML, receptor for advanced glycation end products (RAGE), 
NADPH oxidase 4, phosphorylated p38, core-binding factor α1 (cbfα1), alkaline phosphatase (ALP) and β-actin were 
then performed.
Results: Morphological analysis revealed extensive calcification lesions in the intima and media of the anterior 
tibial artery. The extent and area of calcium deposition in the intima significantly increased with disease progression. 
Interestingly, spotty calcification was predominant in the atherosclerotic plaques of diabetic patients with amputa-
tion, and macrocalcification was almost invisible. Pearson correlation analysis revealed that serum CML level exhibited 
a significant positive correlation with calcium content in the arterial wall (R2 = 0.6141, P < 0.0001). Semi-quantitative 
Western blot analysis suggested that the intensity of CML/RAGE signal increased with progression of atherosclerotic 
calcification in diabetic patients. In subsequent in vitro study, the related pathway was blocked by anti-RAGE antibody, 
NADPH oxidase inhibitor DPI, p38MAPK inhibitor SB203580, and anti-cbfa1 antibody in a step-wise manner to observe 
changes in calcium deposition and molecular signals. Results suggested that CML may play a key role in atheroscle-
rotic calcification mainly through the CML/RAGE- reactive oxygen species (ROS)-p38MAPK-cbfα1-ALP pathway.
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Background
The International Diabetes Federation reported that the 
number of diabetic patients worldwide was 387 million in 
2014 and is predicted to reach 592 million by 2035 [1]. 
China has the highest number of people with diabetes, 
which accounts for about one-third of the total number 
of diabetic patients worldwide [1]. Patients with diabe-
tes commonly manifest vascular calcification, including 
intima and medial calcification, which are mainly distrib-
uted in the coronary artery and lower extremity vessels, 
respectively [2, 3]. A multi-center epidemiological study 
demonstrated that the risk of acute cardiovascular events 
in patients with calcification score  >300 is significantly 
higher than those in patients with calcification score of 
1–100 [4, 5]. Studies showed that the degree of vascular 
calcification could be the optimal predictor of cardiovas-
cular mortality, stroke incidence, and risk of lower limb 
amputation in patients with diabetes mellitus [4–8]. 
Thus, further insights into the mechanism of calcification 
in diabetic atherosclerosis exhibit theoretical and social 
significance.
Vascular calcification is an active process in which vas-
cular smooth muscle cells (VSMCs) adopt an osteoblas-
tic phenotype and deposit hydroxyapatite crystals [9]. 
Our previous studies showed that Nε-carboxymethyl-
lysine (CML), a key active ingredient of heterogeneous 
AGEs, could promote the transdifferentiation of VSMC 
phenotype and the formation of aortic calcification in 
diabetic mice [10]. It’s well known that advanced glyca-
tion end-products (AGEs) are metabolic products of 
glucose toxicity and play a significant role in the devel-
opment of diabetes and its multiple complications. Stud-
ies showed that AGEs could accumulate in many tissues 
and organs, such as skin, kidney, and aorta wall [11, 12]. 
High baseline AGE levels are significantly associated 
with plaque progression after adjusting for diabetes mel-
litus in multivariate logistic regression models [13]. In 
addition, AGE/the receptor for advanced glycation end-
products (RAGE) signal heavily influences both cellular 
and systemic responses to increase bone matrix proteins 
through p38MAPK in both hyperglycemic and calcifi-
cation conditions [14]. The signal in diabetes-mediated 
vascular calcification was also attributed to increased 
oxidative stress resulting in the phenotypic switch of 
VSMCs to osteoblast-like cells in AGEs-induced calcifi-
cation [14].
Then, what’s the relationship among CML/RAGE, 
p38MAPK, reactive oxygen species (ROS), core-binding 
factor α1 (cbfα1, a key transcription factor inducing oste-
oblastic differentiation) and alkaline phosphatase (ALP, 
a specific marker of osteoblastic differentiation) in non-
crosslink and non-fluorescent CML-induced calcifica-
tion? There is no accurate answer. And furthermore, the 
role of CML in the development of atherosclerotic calcifi-
cation in diabetic patients and the underlying mechanism 
also remain unclear. Thus, in the present study, the role 
and the mechanism of CML in the transmission pathway 
of diabetic calcification cascade signal were investigated 
through in  vivo and in  vitro experiments to develop a 
new perspective for prevention and treatment of athero-
sclerotic calcification in diabetes mellitus.
Methods
Materials
CML was purchased from PolyPeptide Laboratories (San 
Diego, USA). Oxidized low density lipoprotein (oxLDL) 
was acquired from Yiyuan Biotechnology (Guangzhou, 
China). RAW264.7 macrophages and A7r5 aortic vas-
cular smooth muscle cells (VSMC) were obtained from 
ATCC (USA). CML ELISA kit, calcium assay, and ALP 
activity kits were provided by Nanjing Jiancheng Bioen-
gineering Institute (Nanjing, China). von Kossa staining 
kit was acquired from Shunbai Biologicals Inc. (Shang-
hai, China). SB203580 (p38MAPK inhibitor) and DPI 
(NADPH oxidase inhibitor) were obtained from Sigma-
Aldrich Co. LLC (USA). Anti-Nε-carboxymethyl-Lysine 
antibody was provided by Abcam (UK). The antibod-
ies against RAGE, NADPH oxidase 4 (Nox4), cbfα1, 
P-p38MAPK, ALP, β-actin, and all secondary antibodies 
were provided by Santa Cruz (USA). All other chemicals 
and reagents were of analytical grade.
Human studies
Type 2 diabetic patients hospitalized for above-knee 
amputation in the Department of Orthopedics, Affili-
ated Hospital of Jiangsu University (Zhenjiang, China) 
were recruited from February 2010 to June 2015 (n = 45). 
All patients were treated with standard insulin therapy 
to control blood glucose. Other comprehensive treat-
ments were used to control local infection, improve 
blood circulation of lower limbs, supply neurotrophic 
drugs, and provide debridement/dressing. According 
Conclusion: Spotty calcification was predominant in the atherosclerotic plaques of amputated diabetic patients. 
CML/RAGE signal may induce the calcification cascade in diabetes via ROS-p38MAPK.
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to the guidelines for prevention and treatment of type 2 
diabetes in China (2013 edition), major amputations are 
performed in the foot of diabetic patients, whose lower 
extremities are ineligible for revascularization because 
of severe ischemia, necrosis, and infection and whose 
wounds could not heal after circulation improvement, 
local debridement, or minor amputation (amputation 
below the ankle joint).
Data regarding age, sex, smoking, duration of diabe-
tes mellitus, hypertension status, fasting plasma glucose 
(FPG), glycated hemoglobin (HbA1c), lipid profile [total 
cholesterol, fasting triglycerides, low-density lipopro-
tein (LDL)-cholesterol, high-density lipoprotein (HDL)-
cholesterol], blood urea nitrogen (BUN) and serum 
creatinine (SCr) were collected before the amputation. 
All patients were divided into three groups based on 
the severity of anterior tibial artery stenosis, which was 
assessed by color Doppler ultrasound: mild stenosis 
group (0% < stenosis < 50%, n = 15), moderate stenosis 
group (50 ≤ stenosis < 70%, n = 15), and severe stenosis/
occlusion group (70 ≤ stenosis ≤ 100%, n = 15). Written 
informed consents were obtained from all patients. This 
study was approved by the Ethical Committee of Jiangsu 
University and conducted in agreement with the institu-
tional guidelines.
Detection of lower extremity arteries by color Doppler 
ultrasound
Related indices of lower extremity arteries were detected 
by Philips HDll color Doppler ultrasound equipped with 
a linear array transducer (7–12 MHz variable frequency). 
The angle between the direction of the sound beam and 
the blood flow was less than 60°. The patients were posi-
tioned in supine position or prone position for all meas-
urements. The femoral artery (FA), popliteal artery (PA), 
anterior tibial artery (ATA), and dorsalis pedis artery 
(DPA) were successively surveyed. Two-dimensional 
ultrasound was used to display the vessel long/short axis 
section images and detect plaque size, number, and vas-
cular diameter. Color Doppler flow imaging (CDFI) was 
used to observe blood flow filling, vascular stenosis, and 
occlusion. The degree of artery stenosis was calculated by 
dividing the residual diameter (N) by the vessel diameter 
at a point distal to the stenosis where the normal ves-
sel caliber was restored (D). The formula is presented as 
follows:
Measurement of serum CML
Serum CML concentration of patients who underwent 
amputation was measured by CML ELISA Kit (Meix-
uan Co. Ltd, Shanghai, China) according to the manu-
facturer’s instructions. The mean minimum detectable 
1−N/D× 100= degree of stenosis
concentration is 0.126  ng/mL. The antibodies in the CML 
kit are highly specific for CML adducts and do not exhibit 
cross reactivity to non-CML proteins in human plasma. 
The intra- and inter-assay coefficients of variation (CV) 
for CML are 5.2–7.4% and 4.7–15.2%, respectively.
Disposal of human specimens
Anterior tibial artery samples were obtained from the 
foot of diabetic patients who underwent lower extremity 
amputation. After perfusion with cold phosphate buffer 
saline (PBS), each artery was cleaned to remove connec-
tive and adipose tissues and then divided longitudinally 
into three pieces. One piece was immediately frozen and 
stored at −80 °C until protein extraction for Western blot 
and ALP activity detection. One piece was used for cal-
cium content detection, and the other piece was fixed in 
10% neutral buffered formalin overnight and embedded 
in paraffin. From the paraffin blocks, 4  μm-thick serial 
sections were examined for hematoxylin–eosin (H&E) 
and von Kossa staining.
Cell studies
RAW264.7 macrophages and A7r5 aortic VSMCs were 
cultured in DMEM/LOWGLUCOSE, supplemented with 
10% fetal bovine serum (FBS), 4.0  mmol/L l-glutamine, 
110  mg/L sodium pyruvate, 100  U/mL penicillin, and 
100  μg/mL streptomycin. After RAW264.7 apoptosis 
induced by 50 μg/mL oxLDL for 48 h, the culture flasks 
were tapped to completely harvest the apoptotic bod-
ies (ABs) as described previously [15]. The supernatant 
culture was centrifuged at 10,000×g (4 °C) for 20 min to 
remove cell debris. The resultant cell-free supernatant 
was re-centrifuged at 150,000×g (4 °C) for 1 h to obtain a 
pellet containing ABs. The pellet was washed three times 
with Hank’s Balanced Salt Solution (without calcium 
or magnesium). Protein content was determined using 
Bradford method.
The specific mechanism of CML in the transmission 
pathway of diabetic calcification cascade signal was also 
investigated using in  vitro experiments. A7r5 VSMCs 
were divided into the following groups: control group 
(A7r5 medium supplemented with 80 μg/mL RAW264.7-
derived-ABs plus 50  μg/mL oxLDL), CML group (A7r5 
medium supplemented with 80  μg/mL RAW264.7-
derived-ABs plus 50  μg/mL oxLDL, and 10  μmol/L 
CML), anti-RAGE group (A7r5 medium supplemented 
with 80  μg/mL RAW264.7-derived-ABs plus 50  μg/mL 
oxLDL, 10 μmol/L CML, and 100 μg/mL antibody against 
RAGE), NADPH oxidase inhibitor group (A7r5 medium 
supplemented with 80  μg/mL RAW264.7-derived-ABs 
plus 50 μg/mL oxLDL, 10 μmol/L CML, and 10 μmol/L 
DPI), p38MAPK inhibitor group (A7r5 medium sup-
plemented with 80  μg/mL RAW264.7-derived-ABs plus 
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50 μg/mL oxLDL, 10 μmol/L CML, and SB203580), and 
anti-cbfα1 group (A7r5 medium supplemented with 
80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, 
10 μmol/L CML, and 100 μg/mL antibody against cbfα1). 
Cells in each group were cultured for 7  days, and the 
medium was replaced every 2 days.
von Kossa staining, calcium content assay, and ALP activity 
assay
von Kossa staining
The A7r5 cell climbing slices were fixed in 4% paraform-
aldehyde for 30  min and then washed twice with dou-
ble-distilled water (ddH2O). The paraffin sections of the 
isolated anterior tibial artery were dewaxed and hydrated. 
Two slices were immersed in 1% silver nitrate for 30 min 
under intense sunbeam or ultraviolet light. The samples 
were then washed in distilled water to remove excess 
reagent, incubated with 5% sodium thiosulfate for 5 min, 
washed once in tap water and several times in distilled 
water, and finally counterstained with eosin (tissue) or 
neutral red (cell) for 10  min. After several washes, the 
slices were observed under an Olympus microscope.
Quantification of calcium content (or deposition)
Calcium content (or deposition) was determined as pre-
viously described [16]. Dried anterior tibial artery and 
A7r5 cells were decalcified with 0.6 N HCl for 24 h. The 
calcium content of HCl supernatant was determined 
colorimetrically through O-cresolphthalein complex-
one method. After the decalcification, the samples were 
washed three times with PBS and solubilized with 0.1 N 
NaOH-0.1% SDS. Protein content was measured using 
Bradford method. Calcium content of the samples was 
normalized with regard to protein content.
ALP activity assay
The ALP activity assay kit uses p-nitrophenyl phosphate 
(pNPP) as a phosphatase substrate, which turns yellow 
(λmax  =  405  nm) when dephosphorylated by ALP. As 
previously described [17], the total proteins of tissues and 
cells were first extracted by centrifugation in RIPA lysis 
buffer. ALP activity was then measured colorimetrically. 
The results were normalized to the levels of total protein 
determined using Bradford method.
Western blot analysis
Total proteins of anterior tibial artery and cells were ini-
tially extracted by centrifugation in RIPA lysis buffer. 
Equal amounts of protein samples were loaded into 10 
or 12% SDS-PAGE gels and transferred onto a polyvi-
nylidene difluoride (PVDF) membrane. The nonspecific 
proteins were blocked with 5% nonfat dried milk for 
1  h. The membranes were incubated with the primary 
antibodies anti-CML (1:5000), anti-RAGE (1:500), anti-
Nox4 (1:500), anti-P-p38 (1:500), anti-cbfα1 (1:500), anti-
ALP (1:500), and anti-β-actin (1:1000) overnight at 4  °C 
as well as with secondary antibody (HRP-conjugated IgG) 
for 1 h. HRP-conjugated secondary antibodies were used 
in conjunction with an ECL chemiluminescence detec-
tion system. Protein expression was analyzed by Gel-Pro 
Analyzer 4 software and normalized to that of β-actin.
Statistical analysis
Data were expressed as mean ± SD and analyzed by SPSS 
13.0 software. For comparison between two variables, 
unpaired Student’s t test was used. Comparison among 
more than two groups was conducted using one-way 
analysis of variance (ANOVA), followed by post hoc LSD 
test. Pearson correlation analysis was used to detect the 
correlation between serum CML level and calcium con-
tent in the arterial wall. A two-tailed P < 0.05 was consid-
ered statistically significant.
Results
Baseline characteristics and laboratory data
Descriptive information regarding baseline characteris-
tics and laboratory results is listed in Table 1. The evalu-
ated indices including age, gender, smoking, diabetes 
duration, hypertension status, fasting plasma glucose, 
lipid profiles, BUN and SCr were not significantly differ-
ent among the three groups. However, CML and HbA1c 
were significantly different among the three groups. 
These findings suggested a poor glycemic control for 
patients undergoing amputation before hospitalization.
Progression of atherosclerotic calcification in the foot 
of diabetic patients
In gross observation, different degrees of gangrene, swell-
ing, skin ulcers, and infection in diabetic foot patients 
were observed among the three groups (Fig.  1). The 
extent/depth of the above lesions in moderate stenosis 
group and severe stenosis/occlusion group became more 
severe compared with the lesions in mild stenosis group. 
The results from two-dimensional ultrasound showed 
that echo-rich plaques (hard plaques) were mainly found 
in the moderate stenosis/severe stenosis/occlusion group, 
whereas echolucent/heterogeneous plaques (soft/hetero-
geneous plaques) were predominant in the mild stenosis 
group. Furthermore, color blood flow in the severe steno-
sis/occlusion group became thin even in the absence of 
blood flow signal by CDFI (Fig. 1).
In contrast to the lesions in the mild/moderate steno-
sis group, advanced atherosclerotic lesions with abun-
dant cholesterol crystals and loss of integrity of the 
intern elastic lamina occurred in the severe stenosis/
occlusion group (Fig.  1). von Kossa staining revealed 
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extensive calcification lesions in the intima and media 
of the anterior tibial artery. Furthermore, the extent and 
area of the calcium deposition in the intima became sig-
nificantly more severe with disease progression (Fig. 1). 
Interestingly, spotty calcification was predominant in the 
atherosclerotic plaques of amputated diabetic patients, 
whereas macrocalcification was almost invisible. Con-
sistently, quantification analysis through O-cresolphtha-
lein complexone method showed that calcium contents 
in the mild stenosis, moderate stenosis, and severe ste-
nosis/occlusion groups are 1.60  ±  0.41, 3.23  ±  0.99, 
and 6.71  ±  1.38  μmol/mg, respectively (Fig.  2). The 
ALP activities in the three groups are 97.5  ±  9.12, 
231.0  ±  31.5, and 541.7  ±  49.2  U/mg, respectively 
(Fig.  2). Our data suggested that atherosclerotic calcifi-
cation in the foot of diabetic patients worsen with steno-
sis progression.
Serum CML level and tissue CML/RAGE signal in the 
progression of atherosclerotic calcification
Serum CML level and tissue CML/RAGE signal in 
diabetic patients were detected by ELISA and West-
ern blot analyses, respectively (Fig.  2). ELISA results 
showed that serum CML levels in the moderate stenosis 
group was increased by 1.28-fold (36.80  ±  5.23 versus 
28.71 ± 4.81 ng/mL, P < 0.001) compared with those in 
the mild stenosis group. The index in the severe stenosis/
occlusion group was increased by 1.57-fold (57.66 ± 6.47 
versus 36.80  ±  5.23  ng/mL, P  <  0.001) compared with 
that in the moderate stenosis group. Pearson correla-
tion analysis revealed a significant positive correla-
tion between serum CML level and calcium content 
in the arterial wall (R2  =  0.6141, P  <  0.0001) (Fig.  2). 
Subsequently, semi-quantitative Western blot analy-
sis indicated that the relative optical densities (target 
protein/β-actin) in the mild stenosis, moderate stenosis, 
and severe stenosis/occlusion groups are 0.106 ± 0.009, 
0.211 ±  0.020, and 0.467 ±  0.054, respectively, in CML 
deposition as well as 0.103 ±  0.006, 0.287 ±  0.030, and 
0.690 ± 0.071 in RAGE expression, respectively (Fig. 2). 
These results suggested that serum CML level and tissue 
CML/RAGE signal increased with progression of athero-
sclerotic calcification in diabetic patients.
Signal pathway of CML‑accelerated calcification 
progression
Studies on diabetic patients and apoE−/− mice [10] indi-
cated the important role of CML in atherosclerotic cal-
cification. However, the mechanism of CML in the 
transmission pathway of diabetic calcification cascade 
signal remains unclear. In our subsequent study, the 
related pathway was blocked by anti-RAGE antibody, 
NADPH oxidase inhibitor DPI, p38MAPK inhibitor 
SB203580, and anti-cbfa1 antibody in a step-wise man-
ner to observe changes in calcium deposition and related 
molecular signals. Calcium deposition was assessed by 
von Kossa staining and O-cresolphthalein complexone 
method. ALP activity and related protein expression were 
Table 1 Baseline characteristics and laboratory data of the studied population
Values are expressed as number (%) or mean ± SD, n = 15 for each group
FPG fasting plasma glucose, HbA1c glycated hemoglobin, LDL low density lipoprotein, HDL high density lipoprotein, BUN blood urea nitrogen, SCr serum creatinine, 
CML Nε-carboxymethyl-lysine
* P < 0.05, compared with the mild stenosis group
#  P < 0.05, compared with the moderate stenosis group
Variables Mild stenosis Moderate stenosis Severe stenosis/occlusion
Males/females 9/6 8/7 8/7
Age (years) 65 ± 9 67 ± 8 71 ± 10
Diabetes duration (years) 10 ± 4 11 ± 5 12 ± 7
Hypertension (%) 67 67 73
Smoking (%) 33 40 33
FPG (mg/dL) 120.61 ± 13.53 130.87 ± 9.81 138.85 ± 15.80
HbA1c (%) 7.50 ± 1.62 9.31 ± 2.43* 12.33 ± 2.79*,#
Total cholesterol (mg/dL) 190.75 ± 32.58 188.51 ± 29.83 208.79 ± 48.13
Triglycerides (mg/dL) 172.51 ± 20.55 181.54 ± 18.73 192.81 ± 21.93
LDL-cholesterol (mg/dL) 142.61 ± 15.93 138.71 ± 12.89 158.71 ± 18.93
HDL-cholesterol (mg/dL) 40.51 ± 7.57 37.95 ± 6.17 41.21 ± 9.73
BUN (mmol/L) 6.03 ± 1.12 6.81 ± 0.73 6.92 ± 1.09
SCr (μmol/L) 103.51 ± 11.92 123.67 ± 8.83 131.54 ± 12.86
CML(ng/mL) 28.71 ± 4.81 36.80 ± 5.23* 57.66 ± 6.47*,#
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examined by ALP kit and semi-quantitative Western blot 
analysis (Figs. 3, 4, 5).
Compared with the indices in the CML-oxLDL-Abs 
group, the anti-RAGE blocking group under high-
lipid, apoptosis-coexisting conditions induced the fol-
lowing changes. ALP activity was inhibited by 51.8% 
(314.5  ±  28.7 versus 652.8  ±  63.3  U/mg, P  <  0.001). 
Intercellular calcium deposition was reduced by 50.6% 
(3.52 ± 0.29 versus 7.12 ± 0.81 μmol/mg, P < 0.001). The 
expression levels of Nox4, P-p38, cbfα1, and ALP were 
decreased by 39.6, 32.5, 53.0, and 55.2%, respectively.
When pretreated with NADPH oxidase inhibi-
tor DPI, ALP activity and Intercellular calcium depo-
sition were reduced by 39.7% (393.6  ±  31.2 versus 
652.8 ±  63.3  U/mg, P  <  0.001) and 33.0% (4.77  ±  0.53 
versus 7.12  ±  0.81  μmol/mg, P  <  0.001), respectively, 
comparing with CML-oxLDL-Abs group. Meanwhile, the 
expression levels of Nox4, P-p38, cbfα1, and ALP in west-
ern blot were decreased by 86.8, 22.4, 49.4, and 33.2%, 
respectively, but there were no significant changes in the 
expression of RAGE.
Subsequently, the treatment with p38MAPK inhibi-
tor SB203580 induced similar changes with DPI: ALP 
activity was inhibited by 44.6% (361.8  ±  33.3 versus 
652.8 ± 63.3 U/mg, P < 0.001) and intercellular calcium 
deposition was reduced by 43.7% (4.01  ±  0.39 versus 
7.12 ±  0.81  μmol/mg, P  <  0.001). However, the expres-
sion levels of P-p38, cbfα1, and ALP were downregulated 
by 88.7, 82.2, and 53.8%, respectively. Interestingly, no 
significant changes in the expression of RAGE and Nox4 
were observed.
Moreover, compared with CML-oxLDL-Abs group, the 
treatment with anti-cbfa1 antibody could inhibite ALP 
activity by 54.5% (297.2 ± 26.5 versus 652.8 ± 63.3 U/mg, 
Fig. 1 Progression of atherosclerotic calcification in diabetic foot patients. (1) In gross observation, different degrees of gangrene, swelling, skin 
ulcers, and infection in diabetic foot patients among the three groups were observed. (2) Ultrasound showed that echo-rich plaques (hard plaques) 
were the majority in the moderate stenosis/severe stenosis/occlusion group, whereas echolucent/heterogeneous plaques (soft/heterogeneous 
plaques) were predominant in the mild stenosis group. Furthermore, color blood flow in the severe stenosis/occlusion group became thin even in 
the absence of blood flow signal by CDFI. (3, 4) Representative photomicrographs of atherosclerotic lesions in anterior tibial artery cross-sections 
after H&E staining (×40) and von Kossa staining (black calcium particles) (×200). von Kossa staining revealed extensive calcification lesions in the 
intima and media of the anterior tibial artery. The extent and area of the calcium deposition in the intima became significantly more severe with 
disease progression. Spotty calcification was predominant in the atherosclerotic plaques of diabetic patients with amputation, whereas macrocalci-
fication was almost invisible
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P < 0.001) and reduced intercellular calcium deposition by 
49.0% (3.63 ± 0.33 versus 7.12 ± 0.81 μmol/mg, P < 0.001). 
And importantly, anti-cbfa1 antibody reduced the expres-
sion level of ALP by 57.1%. However, it had no significant 
effects on the expression of RAGE, Nox4, P-p38, and cbfα1. 
Hence, our data above suggested that CML may play a key 
role in atherosclerotic calcification mainly through CML/
RAGE-ROS-p38MAPK-cbfα1-ALP pathway.
Discussion
Vascular calcification is a significant predictor of coro-
nary heart disease events, stroke, and lower-limb ampu-
tation [18, 19]. Compared with diabetics without vascular 
calcification, diabetics with vascular calcification exhib-
ited a 1.5-fold increase in mortality, a 1.6-fold increase in 
coronary artery disease, a 2.4-fold increase in proteinuria, 
a 1.7-fold increase in retinopathy, and a 5.5-fold increase 
in amputation [20]. Among various types of vascular cal-
cification, spotty calcification (namely microcalcification) 
in atherosclerotic plaques is the most important because 
they promote plaque instability and acute cardiocerebro-
vascular events [19, 21]. Our data showed that spotty 
calcification was widely distributed in the atherosclerotic 
plaques of amputated diabetic patients, which may result 
in the occurrence of diabetic complications. The results 
of molecular biological analysis suggested that CML 
deposition and RAGE expression in the arterial wall were 
upregulated with the development of atherosclerotic 
calcification. Pearson correlative analysis revealed a sig-
nificant positive correlation between serum CML level 
and calcium content in the arterial wall. Furthermore, 
blocking treatments with anti-RAGE antibody could sig-
nificantly inhibit the osteogenic differentiation of A7r5 
smooth muscle cells induced by CML under high-lipid, 
apoptosis-coexisting conditions. Our previous and pre-
sent studies [10] suggested that CML/RAGE signal could 
promote the development of diabetic calcification within 
atherosclerotic plaques. Other studies also suggested 
that the formation of microcalcification and increase in 
plaque instability could be specifically induced by AGEs 
and RAGE signal [22, 23]. However, many inconsistencies 
were observed in existing studies particularly on the pre-
cise pathway through which calcification cascade signals 
are transmitted. Thus, the related mechanism must be 
further elaborated.
The interaction between AGEs and RAGE enhances 
intracellular oxidative stress and promotes the produc-
tion of reactive oxygen species (ROS) [24, 25]. ROS, a 
Fig. 2 Changes in related indices in diabetic foot patients. A Pearson correlative analysis between serum CML level and calcium content in the 
anterior tibial arterial wall. The data revealed a significant positive correlation (R2 = 0.6141, P < 0.0001). B ALP activity in the anterior tibial artery. C 
Protein expression in the anterior tibial arterial wall of diabetic foot patients by Western blot. D Quantitative analysis of relative protein levels (target 
protein/β-actin) by densitometry. Values are expressed as mean ± SD, n = 15 for each group
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Fig. 3 Effects of different treatments on VSMC calcification under high-lipid, apoptosis-coexisting conditions. A Morphology of calcified A7r5 cells 
was detected by von Kossa staining at the light microscopic level (×100). a Control group (A7r5 medium supplemented with 80 μg/mL RAW264.7-
derived-ABs plus 50 μg/mL oxLDL); b CML group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL and 
10 μmol/L CML); c anti-RAGE group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, 10 μmol/L CML, and 
100 μg/mL antibody against RAGE); d NADPH oxidase inhibitor group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs plus 
50 μg/mL oxLDL, 10 μmol/L CML, and 10 μmol/L DPI); e p38MAPK inhibitor group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-
ABs plus 50 μg/mL oxLDL, 10 μmol/L CML, and SB203580); f anti-cbfα1 group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs 
plus 50 μg/mL oxLDL, 10 μmol/L CML, and 100 μg/mL antibody against cbfα1). Cells in each group were cultured for 7 days, and the medium was 
replaced every 2 days. B Calcium depositions were measured utilizing the O-cresolphthalein complexone method and normalized in accordance 
with the cellular protein content. The activity of ALP was analyzed by ALP activity assay kit. Cells were treated similar to A. Values are expressed as 
mean ± SD from the three independent experiments
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by-product of the body’s metabolism, regulates the struc-
ture and function of blood vessel wall and is an important 
physiological/pathological regulatory mediator of intra-
cellular signal cascades [26]. Among the various source 
of ROS generation such as NADPH oxidases, mitochon-
drial electron transport xanthine oxidase, peroxisomes, 
cytochrome P-450 and NO synthases (NOS), the Nox 
family of NADPH oxidases including seven different 
Fig. 5 Molecular mechanism of CML-accelerated VSMC calcification under high-lipid, apoptosis-coexisting conditions. After the cells reached 80% 
confluence, A7r5 aortic smooth muscle cells were cultured in the presence of 50 μg/mL oxLDL and 80 μg/mL RAW264.7-derived-ABs with the indi-
cated treatment for 7 days, and the medium was replaced every 2 days. A, B present quantitative analysis of relative cbfα1, and ALP protein levels 
(target protein/β-actin) by densitometry. Values are expressed as mean ± SD from three independent experiments. a Control group (A7r5 medium 
supplemented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL); b CML group (A7r5 medium supplemented with 80 μg/mL RAW264.7-
derived-ABs plus 50 μg/mL oxLDL, and 10 μmol/L CML); c anti-RAGE group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs 
plus 50 μg/mL oxLDL, 10 μmol/L CML, and 100 μg/mL antibody against RAGE); d NADPH oxidase inhibitor group (A7r5 medium supplemented with 
80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, 10 μmol/L CML, and 10 μmol/L DPI); e p38MAPK inhibitor group (A7r5 medium supple-
mented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, 10 μmol/L CML, and SB203580); f anti-cbfα1 group (A7r5 medium supple-
mented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, 10 μmol/L CML, and 100 μg/mL antibody against cbfα1). Values are expressed 
as mean ± SD from three independent experiments
(See figure on previous page.) 
Fig. 4 Molecular mechanism of CML-accelerated VSMC calcification under high-lipid, apoptosis-coexisting conditions. After the cells reached 80% 
confluence, A7r5 aortic smooth muscle cells were cultured in the presence of 50 μg/mL oxLDL and 80 μg/mL RAW264.7-derived-ABs with the 
indicated treatment for 7 days, and the medium was replaced every 2 days. A Presents the expression of related protein in treated A7r5 cells by 
Western blot. B–D present quantitative analysis of relative RAGE, Nox4 and P-p38 protein levels (target protein/β-actin) by densitometry. Values are 
expressed as mean ± SD from three independent experiments. a Control group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-
ABs plus 50 μg/mL oxLDL); b CML group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, and 10 μmol/L 
CML); c anti-RAGE group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, 10 μmol/L CML, and 100 μg/mL 
antibody against RAGE); d NADPH oxidase inhibitor group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, 
10 μmol/L CML, and 10 μmol/L DPI); e p38MAPK inhibitor group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL 
oxLDL, 10 μmol/L CML, and SB203580); f anti-cbfα1 group (A7r5 medium supplemented with 80 μg/mL RAW264.7-derived-ABs plus 50 μg/mL oxLDL, 
10 μmol/L CML, and 100 μg/mL antibody against cbfα1). Values are expressed as mean ± SD from three independent experiments
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enzymes is the principal source [27–29]. Their wide func-
tions depend not only on the Nox isoform but also on cell 
types. Evidences have suggested NADPH oxidase activity 
in vascular smooth muscles mainly relied on Nox-1, -4, 
and -5 expressions [30, 31]. Furthermore, Nox4-derived 
ROS is involved in the regulation of VSMC phenotype 
differentiation. Once Nox4 is blocked by siRNA, the spe-
cific markers of VSMC could either be lost or downregu-
lated [32, 33]. Given that the osteogenic differentiation of 
VSMC plays a key role in vascular calcification, we sub-
sequently observed changes of Nox4 in the CML/RAGE 
signal pathway.
Early studies revealed that AGEs could mediate the 
activation of p38MAPK signals through ROS [34].In 
addition, cbfα1 serves as a key transcription factor in 
osteogenic differentiation, closely linked with vascular 
calcification [35]. Thus, in order to determine whether 
CML, the major active ingredient of AGEs, could induce 
the cascade of calcification signal through ROS and 
p38MAPK in VSMC, the NADPH oxidase inhibitor DPI, 
p38MAPK inhibitor SB203580 and anti-cbfα1 antibody 
were utilized in present study to observe the mechanism.
Firstly, in the model of CML-accelerated VSMC cal-
cification under high-lipid, apoptosis-coexisting condi-
tions, anti-RAGE antibody, NADPH oxidase inhibitor 
DPI, p38MAPK inhibitor SB203580 and anti-cbfα1 anti-
body significantly inhibited ALP activity and intercellu-
lar calcium deposition, but the specific signal stream was 
unclear. Then the expressions of related signal protein 
were further established. The expression levels of Nox4, 
P-p38, cbfα1 and ALP were significantly decreased when 
pretreated with NADPH oxidase inhibitor DPI, but no 
significant changes in the expression of RAGE, indicating 
that CML/RAGE signal was the upstream signals of Nox-
derived ROS, p38MAPK, cbfα1 and ALP. Subsequently, 
our data showed that the treatment with p38MAPK 
inhibitor SB203580 downregulated the expression of 
P-p38, cbfα1 and ALP. However, no significant changes in 
the expression of RAGE and Nox4 were observed, sug-
gesting p38MAPK, cbfα1 and ALP were the downstream 
molecules of Nox-derived ROS. Now that the expres-
sion of cbfα1 could be significantly inhibited at differ-
ent extents by DPI and SB203580, respectively, blocking 
experiment with anti-cbfα1 antibody was performed. The 
ALP expression was significantly reduced by anti-cbfα1 
antibody. However, no significant changes in the expres-
sion of RAGE, Nox4, P-p38, and cbfα1 were observed, 
which shed light on that cbfα1 was the upstream mol-
ecule of ALP, but downstream molecule of p38MAPK. 
Considering these results, we conclude that CML/
RAGE–ROS-p38MAPK-cbfα1- ALP calcification may be 
the most important cascade of CML/RAGE in diabetic 
calcification.
Conclusion
In conclusion, these findings suggest that spotty calcifi-
cation was predominant in the atherosclerotic plaques 
of amputated diabetic patients and that CML/RAGE 
signal may induce the calcification cascade in diabetes 
via ROS-p38MAPK. On the basis of the target signal of 
the calcification cascade, related drug development and 
subsequent optimization of an intervention strategy 
would provide new opportunities for clinical treatment of 
chronic vascular complications of diabetes.
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